KRAS-Mutant Pancreatic CancerPhase 1NCT07671339
ELI-002 7P + mFOLFIRINOX ± Tislelizumab
ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
What the film says
This trial is for adults with metastatic solid tumors that have an MTAP deletion, such as pancreatic, biliary, esophageal and colon cancers.
The idea: combine BMS-986504, a PRMT5 inhibitor taken by mouth daily, with the chemotherapy pemetrexed, given by vein, in 21 day cycles. MTAP deletion means the MTAP gene is missing.
This phase 1 and 2 study plans 72 patients and first looks at dose limiting side effects. At Northwestern University in Chicago, Devalingam Mahalingam leads it.
Public record; not medical advice.
Sources behind this film
Adults; metastatic solid tumors with MTAP deletion incl. pancreatic, biliary, esophageal, colon; BMS-986504 PRMT5 inhibitor by mouth daily; pemetrexed IV; 21 day cycles; MTAP deletion means gene missing; Phase 1/2; 72 patients; DLT (+1 more lines)
The drug
PRIMARY OBJECTIVE: I. To assess the safety, tolerability and dose limiting toxicity (DLT) of PRMT5 inhibitor BMS-986504 (BMS-986504) in patients with metastatic solid tumors with homozygous deletion of the MTAP gene treated with BMS-986504 in combination with pemetrexed. SECONDARY OBJECTIVES: I. To assess the overall response rate (ORR) in patients with metastatic solid tumors homozygous deletion of the MTAP gene treated with BMS-986504 in combination with pemetrexed. II.
To assess the duration of response (DOR) among patients achieving an objective response, defined as the time from first documented response to disease progression or death. EXPLORATORY OBJECTIVES: I. To descriptively summarize overall survival (OS) in the treated population. II. To descriptively summarize progression-free survival (PFS) in the treated population. III. To descriptively assess the pharmacokinetics of BMS-986504 in combination with pemetrexed.
Giving BMS-986504 in combination with pemetrexed may be safe, tolerable, and/or effective in treating patients with metastatic solid tumors with MTAP deletion.
The study
This phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it first started (primary site) to other places in the body (metastatic). The MTAP gene helps cells recycle important parts needed to make deoxyribonucleic acid (DNA), which is needed for cell growth and function.
MTAP deletion means that the MTAP gene is missing. BMS-986504, a PRMT5 inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.